PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

From: Fast Market Research, Inc.
Published: Fri Mar 04 2016

Meningococcal disease is an acute infection caused by the bacterium Neisseria meningitidis, an aerobic, gram-negative diplococcal microbe that is only pathogenic in humans. Different N. meningitides strains are typically classified into serotypes based on the structure of the polysaccharide capsule surrounding the outer membrane, with five serotypes (A, B, C, W-135, and Y) being responsible for the majority of invasive infections. The meningococci are spread primarily by the exchange of bodily fluids (i.e. saliva) and enter the body by attaching to the epithelial cells of the nasopharynx. Upon adhesion, the bacteria then begin to proliferate and form micro-colonies on the surface of the epithelial cells. Symptoms of systemic infection develop rapidly and include flu-like symptoms (headache, fever, sore throat, nausea, and vomiting), sensitivity to light, and a stiff neck. If left untreated, meningococcal disease progresses rapidly and is often fatal, and a significant population of survivors (10-20%) are left with complications such as loss of a limb, deafness, epilepsy, and mental retardation. Due to the rapid onset and severity of symptoms, vaccination remains the preferred approach to meningococcal disease management and prevention. Currently available vaccines protect against all serotypes A, B, C, W-135, and Y and utilize the polysaccharide as antigens although no single vaccine can protect against all serogroups simultaneously. GlobalData expects growth in the meningococcal vaccines market to be driven by the recent launch of serotype B vaccines, which address a critical unmet need in the treatment landscape, and an increase in the coverage rates of existing routine vaccination programs.

Full Report Details at

Key Questions Answered

* Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the meningococcal vaccine marketplace.
* What will be the effect of recent acquisitions be on the meningococcal vaccine marketplace?
* How will the new first-in class-vaccines against serogroup B be received in the different markets?
* What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
* Which patient population(s) are most likely to be targeted for vaccines against serogroup B?

Key Findings

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »